We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+37.81%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.66B
AUM Growth
+$539M
Cap. Flow
+$598M
Cap. Flow %
12.83%
Top 10 Hldgs %
41.2%
Holding
160
New
26
Increased
26
Reduced
23
Closed
30

Top Buys

Rank Stock Value
1
SEER icon
Seer Inc
SEER
+$372M
2
KRON
Kronos Bio
KRON
+$41.3M
3
SQZ
SQZ Biotechnologies Company
SQZ
+$41M
4
Z icon
Zillow
Z
+$38.7M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$37.2M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$71.8M
2
BABA icon
Alibaba
BABA
+$62.5M
3
MRNA icon
Moderna
MRNA
+$25.3M
4
STNE icon
StoneCo
STNE
+$21.2M
5
SRRK icon
Scholar Rock
SRRK
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 78.81%
2 Consumer Discretionary 9.12%
3 Miscellaneous 6.2%
4 Technology 2.01%
5 Communication Services 1.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NG icon
51
NovaGold Resources
NG
$3.17B
$25.1M 0.54%
2,600,000
– –
FOLD
52
CALL
DELISTED
Amicus Therapeutics
FOLD
$23.1M 0.5%
1,000,000
– –
GOSS icon
53
Gossamer Bio
GOSS
$65.4M
$22.8M 0.49%
29,487
– –
TBIO
54
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$22.1M 0.47%
1,200,000
-200,000
-14% -$3.58M
AGEN
55
Agenus
AGEN
$312M
$21.9M 0.47%
351,555
– –
SLB icon
56
CALL
SLB Ltd
SLB
$79.1B
$21.8M 0.47%
+1,000,000
New +$18.9M
BBIO icon
57
BridgeBio Pharma
BBIO
$14.1B
$21.3M 0.46%
300,000
-100,000
-25% -$4.82M
KURA icon
58
Kura Oncology
KURA
$1.03B
$19.6M 0.42%
600,000
+50,900
+9% +$1.79M
RPTX
59
DELISTED
Repare Therapeutics
RPTX
$19.6M 0.42%
570,000
– –
TECH icon
60
Bio-Techne
TECH
$11.3B
$19.1M 0.41%
240,000
– –
IOVA icon
61
Iovance Biotherapeutics
IOVA
$4.19B
$18.6M 0.4%
400,000
– –
FMTX
62
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$17.4M 0.37%
+500,000
New +$21.8M
TCOM icon
63
Trip.com Group
TCOM
$24.6B
$16.9M 0.36%
500,000
-70,000
-12% -$2.28M
RLAY icon
64
Relay Therapeutics
RLAY
$4.18B
$16.6M 0.36%
400,000
– –
ZYME icon
65
Zymeworks
ZYME
$1.92B
$16.5M 0.36%
+350,000
New +$16.3M
NBTX
66
Nanobiotix
NBTX
$1.88B
$16.5M 0.35%
+1,000,000
New +$17.2M
CRDF icon
67
Cardiff Oncology
CRDF
$102M
$16.2M 0.35%
900,000
– –
KYMR icon
68
Kymera Therapeutics
KYMR
$9.53B
$15.5M 0.33%
250,000
– –
STOK icon
69
Stoke Therapeutics
STOK
$1.87B
$15.5M 0.33%
250,000
-20,750
-8% -$951K
TCRR
70
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$15.5M 0.33%
500,000
– –
IQ icon
71
iQIYI
IQ
$960M
$14.9M 0.32%
+850,000
New +$19.2M
KYNB
72
Kyntra Bio
KYNB
$32.3M
$14.8M 0.32%
16,000
+800
+5% +$841K
CRIS icon
73
Curis
CRIS
$2.72M
$14.8M 0.32%
4,512
+1,000
+28% +$1.2M
BLU
74
DELISTED
BELLUS Health Inc.
BLU
$14.5M 0.31%
4,750,000
+4,275,000
+900% +$11.6M
KRYS icon
75
Krystal Biotech
KRYS
$10.3B
$14.3M 0.31%
237,500
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2020 Portfolio in Review

As of Q4 2020, Artal Group held 160 positions worth $4.66B, up 13% from $4.12B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Artal Group deployed $598M of net new capital in Q4 2020, opening 26 new positions and adding to 26 existing holdings. Its largest new stake was Seer Inc: 5,840,911 shares worth $328M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 58% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was BioNTech, an estimated $71.8M trimmed.

  • Artal Group's largest Q4 2020 buy was Seer Inc: 5,840,911 shares worth $328M.
  • Artal Group added most to Zillow in Q4 2020, an estimated $38.7M increase.
  • Artal Group's biggest Q4 2020 reduction was BioNTech, cutting an estimated $71.8M.
  • Artal Group fully exited StoneCo in Q4 2020, selling an estimated $21.2M.
  • Artal Group's ten largest holdings make up 41% of its $4.66B portfolio in Q4 2020.
  • Artal Group opened 26 new positions and closed 30 in Q4 2020.
  • Artal Group's portfolio value rose 13% quarter-over-quarter to $4.66B.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.